GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in a Virtual Investor CEO Connect segment. The event is scheduled for October 2, 2024, at 12:00 PM ET.
CEO Marc Hertz, PhD, will deliver a brief presentation followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to GRI@jtcir.com. The presentation will be available as a live video webcast on the company's website, with a replay accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI), una compagnia biotecnologica impegnata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione a un segmento Virtual Investor CEO Connect. L'evento è programmato per il 2 ottobre 2024, alle 12:00 PM ET.
Il CEO Marc Hertz, PhD presenterà brevemente seguito da una sessione interattiva di domande e risposte. Gli investitori possono inviare domande in diretta durante l'evento o in anticipo via email a GRI@jtcir.com. La presentazione sarà disponibile come webcast video in diretta sul sito web dell'azienda, con una registrazione accessibile per 90 giorni dopo l'evento.
GRI Bio (NASDAQ: GRI), una empresa biotecnológica enfocada en el desarrollo de moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, ha anunciado su participación en un segmento Virtual Investor CEO Connect. El evento está programado para el 2 de octubre de 2024, a las 12:00 PM ET.
El CEO Marc Hertz, PhD ofrecerá una breve presentación seguida de una sesión interactiva de preguntas y respuestas. Los inversores pueden enviar preguntas en vivo durante el evento o con anticipación por correo electrónico a GRI@jtcir.com. La presentación estará disponible como un webcast de video en vivo en el sitio web de la compañía, con una repetición accesible durante 90 días después del evento.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유성 및 자가 면역 질환을 위한 자연 살해 T 세포(NKT) 조절제 개발에 초점을 맞춘 생명공학 회사로, 가상 투자 CEO 연결 세그먼트에 참여한다고 발표했습니다. 이 행사는 2024년 10월 2일, 오후 12시 ET에 예정되어 있습니다.
CEO Marc Hertz, PhD가 간단한 발표를 한 후, 인터랙티브 Q&A 세션이 이어집니다. 투자자는 행사 중 실시간으로 또는 미리 GRI@jtcir.com으로 이메일을 통해 질문을 제출할 수 있습니다. 발표는 회사 웹사이트에서 라이브 비디오 웹캐스트로 제공되며, 행사가 끝난 후 90일 동안 다시 볼 수 있습니다.
GRI Bio (NASDAQ: GRI), une entreprise de biotechnologie axée sur le développement de modulateurs de cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibrosantes et auto-immunes, a annoncé sa participation à un segment Virtual Investor CEO Connect. L'événement est prévu pour le 2 octobre 2024, à 12h00 ET.
Le PDG Marc Hertz, PhD donnera une brève présentation suivie d'une session interactive de questions et réponses. Les investisseurs peuvent soumettre des questions en direct pendant l'événement ou à l'avance par e-mail à GRI@jtcir.com. La présentation sera disponible en tant que webinaire vidéo en direct sur le site de l'entreprise, avec un replay accessible pendant 90 jours après l'événement.
GRI Bio (NASDAQ: GRI), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von modulatoren der Natural Killer T (NKT) Zellen für entzündliche, fibrotische und autoimmune Krankheiten konzentriert, hat seine Teilnahme an einem Virtual Investor CEO Connect Segment angekündigt. Die Veranstaltung ist für den 2. Oktober 2024, um 12:00 Uhr ET geplant.
CEO Marc Hertz, PhD wird eine kurze Präsentation halten, gefolgt von einer interaktiven Q&A-Sitzung. Investoren können Fragen live während der Veranstaltung oder im Voraus per E-Mail an GRI@jtcir.com einreichen. Die Präsentation wird als Live-Video-Webcast auf der Unternehmenswebsite verfügbar sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
Live video webcast on Wednesday, October 2nd at 12:00 PM ET
LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a Virtual Investor CEO Connect segment on October 2, 2024 at 12:00 PM ET.
As part of the event, Dr. Hertz will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing GRI@jtcir.com. Time permitting, the Company will respond to submitted questions.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
When is GRI Bio (NASDAQ: GRI) participating in the Virtual Investor CEO Connect segment?
Who will be presenting at the GRI Bio (NASDAQ: GRI) Virtual Investor event?
How can investors submit questions for the GRI Bio (NASDAQ: GRI) Virtual Investor event?
Where can I watch the GRI Bio (NASDAQ: GRI) Virtual Investor presentation?
How long will the GRI Bio (NASDAQ: GRI) Virtual Investor presentation replay be available?
